Paper33708784
Therapeutic Insights in Chronic Kidney Disease Progression.
Shabaka A and 2 others. Front Med (Lausanne), 2021. Cited by 57 papers, by iCite.
Cite this record
ConductScience Library. Therapeutic Insights in Chronic Kidney Disease Progression. Papers, record 33708784. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33708784
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References76
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19608703 | Bicarbonate supplementation slows progression of CKD and improves nutritional status. | J Am Soc Nephrol | 2009 | https://conductscience.org/library/papers/19608703 | PubMed |
| 2 | 26774608 | Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. | Lancet Diabetes Endocrinol | 2016 | https://conductscience.org/library/papers/26774608 | PubMed |
| 3 | 20413961 | Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? | Am J Nephrol | 2010 | https://conductscience.org/library/papers/20413961 | PubMed |
| 4 | 24107852 | Bicarbonate therapy for prevention of chronic kidney disease progression. | Kidney Int | 2014 | https://conductscience.org/library/papers/24107852 | PubMed |
| 5 | 22436957 | Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. | JAMA | 2012 | https://conductscience.org/library/papers/22436957 | PubMed |
| 6 | 23121378 | Cardiorenal end points in a trial of aliskiren for type 2 diabetes. | N Engl J Med | 2012 | https://conductscience.org/library/papers/23121378 | PubMed |
| 7 | 17460140 | Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. | J Am Soc Nephrol | 2007 | https://conductscience.org/library/papers/17460140 | PubMed |
| 8 | 21541658 | Mechanisms and consequences of TGF-ß overexpression by podocytes in progressive podocyte disease. | Cell Tissue Res | 2012 | https://conductscience.org/library/papers/21541658 | PubMed |
| 9 | 25441440 | Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study. | Am J Kidney Dis | 2014 | https://conductscience.org/library/papers/25441440 | PubMed |
| 10 | 29992892 | Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship? | Curr Cardiol Rev | 2019 | https://conductscience.org/library/papers/29992892 | PubMed |
| 11 | 27299675 | Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27299675 | PubMed |
| 12 | 32970396 | Dapagliflozin in Patients with Chronic Kidney Disease. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32970396 | PubMed |
| 13 | 30361325 | DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. | J Am Soc Nephrol | 2018 | https://conductscience.org/library/papers/30361325 | PubMed |
| 14 | 22490878 | Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. | Clin J Am Soc Nephrol | 2012 | https://conductscience.org/library/papers/22490878 | PubMed |
| 15 | 23608655 | Endothelin, kidney disease, and hypertension. | Hypertension | 2013 | https://conductscience.org/library/papers/23608655 | PubMed |
| 16 | 27733283 | Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. | Lancet | 2016 | https://conductscience.org/library/papers/27733283 | PubMed |
| 17 | 28284376 | The Tubulointerstitial Pathophysiology of Progressive Kidney Disease. | Adv Chronic Kidney Dis | 2017 | https://conductscience.org/library/papers/28284376 | PubMed |
| 18 | 16123474 | Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. | Diabetes Care | 2005 | https://conductscience.org/library/papers/16123474 | PubMed |
| 19 | 15516696 | Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15516696 | PubMed |
| 20 | 24904085 | Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. | J Am Soc Nephrol | 2014 | https://conductscience.org/library/papers/24904085 | PubMed |
Cited by43
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 57 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42656977 | Modulating Renal Fibrosis: The Emerging Role of Hepatocyte Growth Factor. | Int J Nephrol | 2026 | https://conductscience.org/library/papers/42656977 | PubMed |
| 42179848 | Efficacy and safety of finerenone in chronic kidney disease stages 3-4 in diabetic and non-diabetic patients with an eGFR 20-60 mL/min: a prospective cohort study. | Front Nephrol | 2026 | https://conductscience.org/library/papers/42179848 | PubMed |
| 42133559 | Potential Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Regulating Cardiac and Renal Fibrosis. | Cardiorenal Med | 2026 | https://conductscience.org/library/papers/42133559 | PubMed |
| 41588213 | Blood pressure and renal function decline in apparently healthy adults: the tehran lipid and glucose study. | J Hum Hypertens | 2026 | https://conductscience.org/library/papers/41588213 | PubMed |
| 41516982 | Translational Lifestyle Medicine Approaches to Cardiovascular-Kidney-Metabolic Syndrome. | Healthcare (Basel) | 2025 | https://conductscience.org/library/papers/41516982 | PubMed |
| 41348383 | The role of amino acid signaling in pathogenesis of chronic kidney disease. | Mol Cell Biochem | 2026 | https://conductscience.org/library/papers/41348383 | PubMed |
| 40872522 | Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40872522 | PubMed |
| 40607119 | Targeted co-delivery of IL-10 and catalase for cooperative therapeutic effect on acute kidney injury. | Bioact Mater | 2025 | https://conductscience.org/library/papers/40607119 | PubMed |
| 40474975 | Bupropion decreases plasma levels of asymmetric dimethylarginine and ameliorates renal injury by modulation of Ddah1, Oatp4c1, Oct2, and Mate1 in rats with adenine-induced chronic renal injury. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40474975 | PubMed |
| 40454508 | Beyond Traditional Silos: An Integrated Framework Leveraging Novel Pathways for Reducing Cardio-renal Risk in Type 2 Diabetes. | Curr Diabetes Rev | 2026 | https://conductscience.org/library/papers/40454508 | PubMed |
| 40027896 | Advances in kidney disease: pathogenesis and therapeutic targets. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/40027896 | PubMed |
| 39848232 | Personalized Care in CKD: Moving Beyond Traditional Biomarkers. | Nephron | 2025 | https://conductscience.org/library/papers/39848232 | PubMed |
| 39525849 | Dysregulation of the 3β-hydroxysteroid dehydrogenase type 2 enzyme and steroid hormone biosynthesis in chronic kidney disease. | Front Endocrinol (Lausanne) | 2024 | https://conductscience.org/library/papers/39525849 | PubMed |
| 39450151 | An In Situ Sustained-Release Chitosan Hydrogel to Attenuate Renal Fibrosis by Retaining Klotho Expression. | Biomater Res | 2024 | https://conductscience.org/library/papers/39450151 | PubMed |
| 39196533 | Renal Protective Effect of Umbelliferone on Acute Kidney Injury in Rats via Alteration of HO-1/Nrf2 and NF-κB Signaling Pathway. | Dokl Biochem Biophys | 2024 | https://conductscience.org/library/papers/39196533 | PubMed |
| 38835403 | Chronic Kidney Disease in Brazil: Current Status and Recommended Improvements. | Kidney Dis (Basel) | 2024 | https://conductscience.org/library/papers/38835403 | PubMed |
| 38255158 | Adiponectin C1q/Tumor Necrosis Factor-Related Protein 13 (CTRP13) Protects against Renal Inflammation and Fibrosis in Obstructive Nephropathy. | Biomedicines | 2023 | https://conductscience.org/library/papers/38255158 | PubMed |
| 38196830 | Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective. | Int J Nephrol Renovasc Dis | 2024 | https://conductscience.org/library/papers/38196830 | PubMed |
| 38186336 | Serum vitamin C levels and their correlation with chronic kidney disease in adults: a nationwide study. | Ren Fail | 2024 | https://conductscience.org/library/papers/38186336 | PubMed |
| 38169578 | Beneficial effects of physical exercise on the osteo-renal Klotho-FGF-23 axis in Chronic Kidney Disease: A systematic review with meta-analysis. | Int J Med Sci | 2024 | https://conductscience.org/library/papers/38169578 | PubMed |
Genes20
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33708784
GET https://conductscience.org/api/papers/v1/33708784/references?page=2